NO20075000L - Kondenserte aromatiske forbindelser med anti-diabetisk aktivitet - Google Patents
Kondenserte aromatiske forbindelser med anti-diabetisk aktivitetInfo
- Publication number
- NO20075000L NO20075000L NO20075000A NO20075000A NO20075000L NO 20075000 L NO20075000 L NO 20075000L NO 20075000 A NO20075000 A NO 20075000A NO 20075000 A NO20075000 A NO 20075000A NO 20075000 L NO20075000 L NO 20075000L
- Authority
- NO
- Norway
- Prior art keywords
- aromatic compounds
- condensed aromatic
- diabetic activity
- diabetes
- type
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65866105P | 2005-03-04 | 2005-03-04 | |
| PCT/US2006/007740 WO2006096564A1 (en) | 2005-03-04 | 2006-03-03 | Fused aromatic compounds having anti-diabetic activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20075000L true NO20075000L (no) | 2007-11-30 |
Family
ID=36615702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20075000A NO20075000L (no) | 2005-03-04 | 2007-10-03 | Kondenserte aromatiske forbindelser med anti-diabetisk aktivitet |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7834036B2 (ko) |
| EP (1) | EP1861382B1 (ko) |
| JP (1) | JP4638512B2 (ko) |
| KR (1) | KR20070110324A (ko) |
| CN (2) | CN102584754B (ko) |
| AU (1) | AU2006220809B2 (ko) |
| BR (1) | BRPI0609352A2 (ko) |
| CA (1) | CA2598725C (ko) |
| CR (1) | CR9401A (ko) |
| ES (1) | ES2393793T3 (ko) |
| IL (1) | IL185394A0 (ko) |
| MA (1) | MA29352B1 (ko) |
| MX (1) | MX2007010745A (ko) |
| NI (1) | NI200700200A (ko) |
| NO (1) | NO20075000L (ko) |
| RU (1) | RU2007136784A (ko) |
| WO (1) | WO2006096564A1 (ko) |
| ZA (1) | ZA200706394B (ko) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1993543A2 (en) * | 2006-03-03 | 2008-11-26 | Merck & Co., Inc. | Novel crystalline forms of antidiabetic compounds |
| WO2008109334A1 (en) | 2007-03-02 | 2008-09-12 | Merck & Co., Inc. | Novel crystalline salt form of an antidiabetic compound |
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| CA2688187C (en) * | 2007-05-07 | 2016-10-11 | Merck & Co., Inc. | Method of treament using fused aromatic compounds having anti-diabetic activity |
| US20120035105A1 (en) * | 2009-01-09 | 2012-02-09 | Sdg, Inc. | Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments |
| WO2014134776A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| CN104725219B (zh) * | 2015-02-11 | 2017-08-08 | 华中农业大学 | S‑2‑(4‑甲氧基苯氧基)丙酸钠的制备方法 |
| AR110038A1 (es) | 2016-05-26 | 2019-02-20 | Kalyra Pharmaceuticals Inc | Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos |
| EP3740206B1 (en) | 2018-01-16 | 2024-03-06 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| AU2019209470A1 (en) | 2018-01-16 | 2020-08-13 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| JP2022515705A (ja) | 2018-11-01 | 2022-02-22 | サイロス ファーマシューティカルズ， インコーポレイテッド | サイクリン依存性キナーゼ７（ｃｄｋ７）の非共有結合性阻害剤を用いてバイオマーカーにより特定された患者におけるがんを処置する方法 |
| US20240109865A1 (en) | 2020-12-30 | 2024-04-04 | Tyra Biosciences, Inc. | Indazole compounds as kinase inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003525217A (ja) | 1999-10-22 | 2003-08-26 | メルク エンド カムパニー インコーポレーテッド | 肥満治療用薬剤 |
| AU784722B2 (en) * | 2000-02-18 | 2006-06-01 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
| JP2001354671A (ja) * | 2000-04-14 | 2001-12-25 | Nippon Chemiphar Co Ltd | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
| ATE362468T1 (de) | 2000-07-25 | 2007-06-15 | Merck & Co Inc | N-substituierte indole mit anwendung in der behandlung von diabetes |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| AU2002251978B2 (en) | 2001-02-09 | 2007-07-19 | Merck & Co., Inc. | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
| JP4542757B2 (ja) * | 2002-08-08 | 2010-09-15 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| EP1527049B8 (en) | 2002-08-08 | 2008-10-29 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds as peptidase inhibitors |
| CN100457730C (zh) | 2002-08-29 | 2009-02-04 | 默克公司 | 具有抗糖尿病活性的吲哚化合物 |
| US7393960B2 (en) * | 2002-08-29 | 2008-07-01 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| ATE488236T1 (de) * | 2004-09-16 | 2010-12-15 | Merck Sharp & Dohme | Verbindungen zur behandlung von dyslipidämie und anderer lipidstörungen |
-
2006
- 2006-03-03 ES ES06736976T patent/ES2393793T3/es active Active
- 2006-03-03 CN CN201110409206.6A patent/CN102584754B/zh not_active Expired - Fee Related
- 2006-03-03 RU RU2007136784/04A patent/RU2007136784A/ru not_active Application Discontinuation
- 2006-03-03 BR BRPI0609352-3A patent/BRPI0609352A2/pt not_active IP Right Cessation
- 2006-03-03 CN CNA2006800062459A patent/CN101128441A/zh active Pending
- 2006-03-03 CA CA2598725A patent/CA2598725C/en not_active Expired - Fee Related
- 2006-03-03 AU AU2006220809A patent/AU2006220809B2/en not_active Ceased
- 2006-03-03 EP EP06736976A patent/EP1861382B1/en active Active
- 2006-03-03 US US11/884,802 patent/US7834036B2/en active Active
- 2006-03-03 KR KR1020077020253A patent/KR20070110324A/ko not_active Application Discontinuation
- 2006-03-03 WO PCT/US2006/007740 patent/WO2006096564A1/en active Application Filing
- 2006-03-03 JP JP2007558289A patent/JP4638512B2/ja not_active Expired - Fee Related
- 2006-03-03 MX MX2007010745A patent/MX2007010745A/es unknown
-
2007
- 2007-08-01 ZA ZA200706394A patent/ZA200706394B/xx unknown
- 2007-08-08 NI NI200700200A patent/NI200700200A/es unknown
- 2007-08-20 IL IL185394A patent/IL185394A0/en unknown
- 2007-09-27 CR CR9401A patent/CR9401A/es unknown
- 2007-09-27 MA MA30253A patent/MA29352B1/fr unknown
- 2007-10-03 NO NO20075000A patent/NO20075000L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1861382A1 (en) | 2007-12-05 |
| JP2008531729A (ja) | 2008-08-14 |
| MA29352B1 (fr) | 2008-03-03 |
| AU2006220809B2 (en) | 2009-06-11 |
| JP4638512B2 (ja) | 2011-02-23 |
| CA2598725A1 (en) | 2006-09-14 |
| ZA200706394B (en) | 2008-09-25 |
| RU2007136784A (ru) | 2009-04-10 |
| CA2598725C (en) | 2010-10-26 |
| IL185394A0 (en) | 2008-02-09 |
| KR20070110324A (ko) | 2007-11-16 |
| US7834036B2 (en) | 2010-11-16 |
| CN102584754B (zh) | 2016-02-03 |
| WO2006096564A1 (en) | 2006-09-14 |
| EP1861382B1 (en) | 2012-10-10 |
| CN102584754A (zh) | 2012-07-18 |
| MX2007010745A (es) | 2007-09-12 |
| AU2006220809A1 (en) | 2006-09-14 |
| CN101128441A (zh) | 2008-02-20 |
| US20080194586A1 (en) | 2008-08-14 |
| CR9401A (es) | 2008-02-21 |
| ES2393793T3 (es) | 2012-12-28 |
| BRPI0609352A2 (pt) | 2011-10-18 |
| NI200700200A (es) | 2008-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20075000L (no) | Kondenserte aromatiske forbindelser med anti-diabetisk aktivitet | |
| NO20051546L (no) | Indoler med anti-diabetisk aktivitet | |
| ATE472531T1 (de) | Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1 | |
| WO2004019869A3 (en) | Indoles having anti-diabetic activity | |
| WO2004066963A3 (en) | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives | |
| NO20063720L (no) | Antidiabetiske oksazolidiendioner og tiazolidiendioner | |
| NO20044534L (no) | Substituerte fenylacetamider og deres anvendelse som glukokinaseaktivatorer | |
| NO20054396D0 (no) | 3-metyl-2-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksankarbonyl-amino)-smorsyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose | |
| ATE476425T1 (de) | Triazolderivate als inhibitoren von 11-beta- hydroxysteroid-dehydrogenase-1 | |
| DE602004007693D1 (de) | (3-oxo-3,4-dihydro-chinoxalin-2-yl-amino)-benzamid-derivate und verwandte verbindungen als glykogen-phosphorylase-hemmer zur behandlung von diabetes und adipositas | |
| CL2008000067A1 (es) | Compuestos derivados de espirocromanona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, higado graso, hiperlipemia, obesidad, diabetes, bulimia, neoplasma maligno o enfermedades infecciosas. | |
| CL2007003176A1 (es) | Compuestos derivados de nicotinamida, inhibidores de 11betahsd1; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, la diabetes tipo 2, obesidad o aterosclerosis. | |
| NO20083026L (no) | Terapeutisk middel for diabetes | |
| CL2011001497A1 (es) | Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico. | |
| NO20092034L (no) | Kjemiske forbindelser og anvendelser | |
| WO2006127503A3 (en) | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | |
| WO2006084176A3 (en) | Compounds and compositions as ppar modulators | |
| CL2007001886A1 (es) | Compuestos derivados de ureas de piperidina o pirrolidina; procedimiento de preparación; composición farmacéutica; y su uso como moduladores de la actividad de la 11ß-hidroxiesteroide deshidrogenasa tipo 1 (11ßhsd1) para tratar la obesidad, diabetes, resistenacia a la insulina, síndrome de cushing e hipertensión, entre otros. | |
| DE502006007587D1 (de) | Substituierte 2-aminoalkylthio-benzimidazole und ihre verwendung zur blutzuckersenkung | |
| WO2006014262A3 (en) | Indoles having anti-diabetic activity | |
| PL1848700T3 (pl) | Sole kwasu (s)-2-amino-3-{4-[4-(2,4-diokso-tiazolidyn-5-ylometylo)- fenoksy]-fenylo}-propionowego i jego estrów metylowych jako inhibitory interleukiny do leczenia otyłości lub cukrzycy | |
| ATE504595T1 (de) | Il-22 zur behandlung von fettleibigkeit, diabetes,hyperlipidämie, hyperglykämie und insulinresistenz | |
| DK1789403T3 (da) | N-(phenyl-oxazol-4ylmethoxymethyl)-cyclohexyl-ravsyreamid derivater og beslægtede forbindelser som PPAR-ligander (peroxisom-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes | |
| ATE515494T1 (de) | Neue verbindungen, deren herstellung und verwendung | |
| BRPI0607085A2 (pt) | derivados de oximas heterocìclicos, o respectivo processo de preparação e a respectiva utilização como agentes hipoglicemiantes e hipolipemiantes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |